Zhou Jian-Mei, Zhou Jian-Hu, Deng Zheng-Hao, Zheng Hui, Jiang Hai-Ying, Cao Hui-Qiu
Department of Anaesthesiology, Second Xiangya Hospital, Central South University, Changsha, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Oct;30(5):544-8.
To determine the expressions of survivin and proliferating cell nuclear antigen (PCNA)in non-small cell lung cancer (NSCLC) and to explore its clinical pathological significance.
Immunohistochemical SP method was used to detect the expressions of survivin and PCNA in 43 patients with NSCLC and 15 normal epithelial tissues of the lung. PCNA labeling proliferative index was assessed. Forty-three patients with NSCLC were followed up for more than 5 years.
The positive expression of survivin in NSCLC (79.1%) was significantly higher than that in normal epithelial tissues of the lung (P < 0.01). The survivin expression in Stage I + II was lower than in Stage III (P < 0.05). The overall survival time was significantly shorter in patients with high survivin expression than that in patients with absent or low survivin expression. The survivin expression was not related to sex, age, tumor size and site, histological type, grade, and lymphoid node metastasis (P > 0.05). The mean proliferative index of PCNA in NSCLC was much higher than that in normal epithelial tissues of the lung (P < 0.01). A positive correlation was present between the proliferative index and the tumor size, lymph node metastase, and clinical stage (P <0.01), while a negative correlation between the proliferative index and survival time (P <0.01). There was no correlation between proliferative index and age, sex, site, histological type and grade. The proliferative index was larger in patients with moderate or strong positive survivin expression than that in patients with negative or weak survivin expression (P < 0.05).
Over expression of survivin and PCNA is closely correlated to the progression and prognosis of patients with NSCLC, which is helpful to evaluate the progression of cancer and to predict the prognosis of NSCLC. The up-regulation of survivin expression and its close relationship with the cell proliferation in NSCLC suggest that survivin may play an important role in the carcinogenesis and development of lung cancer.
检测非小细胞肺癌(NSCLC)中生存素(survivin)和增殖细胞核抗原(PCNA)的表达,探讨其临床病理意义。
采用免疫组织化学SP法检测43例NSCLC患者及15例正常肺上皮组织中survivin和PCNA的表达,评估PCNA标记增殖指数。对43例NSCLC患者进行5年以上随访。
NSCLC中survivin阳性表达率(79.1%)显著高于正常肺上皮组织(P<0.01)。Ⅰ+Ⅱ期survivin表达低于Ⅲ期(P<0.05)。survivin高表达患者的总生存时间显著短于无或低表达患者。survivin表达与性别、年龄、肿瘤大小和部位、组织学类型、分级及淋巴结转移无关(P>0.05)。NSCLC中PCNA的平均增殖指数远高于正常肺上皮组织(P<0.01)。增殖指数与肿瘤大小、淋巴结转移及临床分期呈正相关(P<0.01),与生存时间呈负相关(P<0.01)。增殖指数与年龄、性别、部位、组织学类型及分级无关。survivin中度或强阳性表达患者的增殖指数大于阴性或弱阳性表达患者(P<0.05)。
survivin和PCNA的过表达与NSCLC患者的病情进展及预后密切相关,有助于评估癌症进展及预测NSCLC的预后。NSCLC中survivin表达上调及其与细胞增殖的密切关系提示survivin可能在肺癌的发生发展中起重要作用。